Helus Pharma stock closes at $8.87 below daily and hourly averages

Related

AI-automated software exploitation leaves organizations less time to patch

Attackers are using AI-automated software exploitation to find and...

Uphold’s MiCA authorization under EU crypto rules permits Europe-wide operations

According to the company’s statement on November 16, 2026,...

Blockchain, Digital Payments and Online Entertainment Platforms

Blockchain and digital payments are often discussed as if...

Tudor Investment’s Bitcoin ETF holdings rose 98% in Q3 to 1.36M shares

Tudor Investment’s Bitcoin ETF holdings nearly doubled in the...

Tether’s USDT payments expansion taps Stables’ reach in over 160 markets

Tether’s USDT payments expansion is moving through regional fintech...

Share

Helus Pharma stock carries a bearish daily bias into the next session, despite holding above its 200-session exponential moving average. The hourly chart supports that cautious reading. A positive 15-minute MACD histogram offers a limited counterpoint, but does not outweigh the broader price structure.

HELP daily chart with EMA20, EMA50 and volume
HELP — daily chart with candlesticks, EMA20/EMA50 and volume.

Key takeaways

  • HELP closed at $8.87 on Friday, November 13, 2026, with a gain of 0.11%.
  • The close sits below the daily 20-session EMA ($9.69) and 50-session EMA ($10.35) but above the 200-session EMA ($8.81).
  • Daily RSI14 is 39.16, below 50; daily MACD histogram is -0.01.
  • Hourly RSI14 is 43.7, and the close sits below all three hourly EMAs.
  • Next-session daily pivot is $8.81, with first resistance at $9.12 and first support at $8.56.

In Friday’s session, November 13, 2026, HELP opened at $8.91, traded between a low of $8.50 and a high of $9.06, and closed at $8.87, against a previous close of $8.86. That was a gain of 0.11% versus the previous close.

Meanwhile, a report published on Sunday, November 15, said Helus Pharma was scheduled to present Phase 3 depression trial results on Monday, November 16. The report appeared on a later day than Friday’s session and cannot explain that session’s move. It establishes a scheduled presentation, not the trial’s outcome.

Helus Pharma stock faces daily resistance above support

On the daily timeframe, the close sits below the 20-session EMA at $9.69 and the 50-session EMA at $10.35. Those averages define overhead resistance. However, the close remains above the 200-session EMA at $8.81, so the daily averages do not form a fully bearish alignment.

Daily RSI14 stands at 39.16, below 50 but above oversold territory. At the same time, the MACD line is -0.63, below its signal at -0.61, with a negative histogram of -0.01. Together, these readings support the bearish bias without an oversold RSI condition.

Moreover, the close sits below the daily Bollinger mid-band at $9.78, between the lower band at $8.03 and upper band at $11.53. That places price in the lower half of the band structure. Daily ATR14 reads $0.83, providing a volatility reference rather than a directional signal.

When trading resumes, the daily pivot for the next session sits at $8.81. Daily first resistance is $9.12, and daily first support is $8.56. Notably, these levels are calculated from the completed daily candle and frame the next session, not Friday’s trading.

Hourly confirmation, with a short-term conflict

Meanwhile, HELP’s $8.87 close sits below the hourly 20-hour EMA at $8.99, the 50-hour EMA at $9.14, and the 200-hour EMA at $10.23. As a result, price and those averages are bearishly aligned. Hourly RSI14 is 43.7, below 50. Additionally, the hourly MACD line of -0.09 is below its signal of -0.07, reinforcing the daily caution.

In contrast, the 15-minute MACD line is 0, above its signal at -0.01, with a positive histogram of 0.01. That is a short-term counterweight, not confirmation of a bullish daily setup. Still, the 15-minute RSI14 remains below 50 at 46.94.

For execution context, the close equals the 15-minute Bollinger mid-band at $8.87. It remains below the 20-period EMA at $8.89, the 50-period EMA at $8.96, and the 200-period EMA at $9.16. The positive MACD histogram therefore conflicts with bearish average alignment on this timeframe.

Bullish and bearish conditions for the next session

For the next session, a bullish case requires holding the daily 200-session EMA and next-session daily pivot, both at $8.81. Initially, clearing the hourly 20-hour EMA at $8.99 would address the first overhead average. A sustained move above next-session daily first resistance at $9.12 would strengthen that case. The daily 20-session EMA at $9.69 would then be the next broader reference.

Conversely, a break below $8.81 would undermine that bullish case. Next-session daily first support at $8.56 would then become the immediate reference, followed by Friday’s low at $8.50. In that scenario, a break below both would leave the daily lower Bollinger band at $8.03 as the lower chart reference.

Overall, Helus Pharma stock stands above $8.81 support but below its hourly and daily overhead averages. Daily ATR14 of $0.83 frames the volatility. The unresolved questions are whether support holds and what the planned trial-results presentation contains.

FAQ

Where does HELP stand relative to its daily moving averages?

HELP’s close at $8.87 sits below the 20-session EMA ($9.69) and the 50-session EMA ($10.35), but remains above the 200-session EMA ($8.81). The averages do not form a fully bearish alignment.

What levels should traders watch in the next session?

The daily pivot for the next session is $8.81, with first resistance at $9.12 and first support at $8.56. The 200-session EMA also sits at $8.81, reinforcing that level. Friday’s low at $8.50 and the daily lower Bollinger band at $8.03 are additional references below.

What does the hourly chart indicate for HELP?

The hourly chart shows the close below all three hourly EMAs — the 20-hour at $8.99, the 50-hour at $9.14, and the 200-hour at $10.23. Hourly RSI14 is 43.7, below 50, and the hourly MACD line is below its signal, reinforcing the bearish bias.


Disclaimer: This article is for informational purposes only and does not constitute financial advice, an investment recommendation, or a solicitation to buy or sell any financial instrument. The analysis provided is not indicative of future results. Investing in financial markets carries a high risk of capital loss. Always do your own research (DYOR) and consult a qualified financial advisor before making any decision.

Cryptonomist and the author hold no positions in the financial instruments mentioned and receive no compensation from the companies covered.

Read also: NeuroPace stock falls 47.3%, from $12.02 to $6.33 as of 14:19 ET

Article produced with the assistance of artificial intelligence and reviewed by the editorial team.